L A Beste

Summary

Country: USA

Publications

  1. ncbi Redesign of chronic care for hepatitis C in a Rhode Island homeless population based on provider compliance with hepatitis C guidelines
    Lauren A Beste
    Department of Internal Medicine, Rhode Island Hospital, USA
    Med Health R I 91:116-8. 2008
  2. ncbi Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C
    L A Beste
    Health Services Research and Development Center of Excellence, VA Puget Sound Healthcare System, Seattle, WA 98101, USA
    Aliment Pharmacol Ther 30:275-82. 2009
  3. ncbi Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication
    Lauren A Beste
    Health Services Research and Development Center of Excellence, VA Puget Sound Healthcare System, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 8:972-8. 2010

Detail Information

Publications3

  1. ncbi Redesign of chronic care for hepatitis C in a Rhode Island homeless population based on provider compliance with hepatitis C guidelines
    Lauren A Beste
    Department of Internal Medicine, Rhode Island Hospital, USA
    Med Health R I 91:116-8. 2008
  2. ncbi Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C
    L A Beste
    Health Services Research and Development Center of Excellence, VA Puget Sound Healthcare System, Seattle, WA 98101, USA
    Aliment Pharmacol Ther 30:275-82. 2009
    ..specialists with respect to patient-centred outcomes, such as disease-specific knowledge, health-related quality of life (HRQoL) and satisfaction with care...
  3. ncbi Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication
    Lauren A Beste
    Health Services Research and Development Center of Excellence, VA Puget Sound Healthcare System, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 8:972-8. 2010
    ..Risk factors for discontinuation before 48 weeks among patients with genotype 1 HCV vary over the course of therapy. We investigated the rates and risk factors for treatment discontinuation within 12 weeks, 12-24 weeks, and 24-48 weeks...